Health Care/Hospital

The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval

YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of "GC1109", an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA), to the Korean Ministry of Food and Drug...

2023-11-06 09:11 1300

PillWork's Upcoming Launch and its Landmark Partnership with Precision Nutrition Association

SEOUL, South Korea, Nov. 5, 2023 /PRNewswire/ -- With much anticipation surrounding its impending release, PillWork officially announces its launch scheduled for the end of 2023. An integral part of this excitement is the company's crucial alliance with the esteemed Precision Nutrition Associatio...

2023-11-06 09:00 1226

Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy

SHANGHAI, Nov. 4, 2023 /PRNewswire/ -- On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clin...

2023-11-05 08:00 2276

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...

2023-11-03 12:10 618

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...

2023-11-03 09:15 593

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...

2023-11-03 09:10 543

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 482

Complete Genomics and Basepair™ Announce Technology Integration Partnership

SAN JOSE, Calif. and NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Complete Genomics and Basepair, Inc today announced a technology integration partnership to accelerate the analysis and interpretation of genomic data generated by Complete Genomics' DNBSEQTM sequencing platforms*. The partnership gives ...

2023-11-02 21:00 735

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...

2023-11-02 20:00 507

Boryung Successfully Concludes 'Humans In Space Symposium' at 2023 ASCEND in Las Vegas

* HIS Symposium co-located with ASCEND, the world's event designed to accelerate the building of our sustainable off-world future, fromOctober 23 to 25. * Jay Kim, the Chairman and CEO of Boryung, invited as a speaker for ASCEND's opening and closing ceremonies and the panel discussion. * B...

2023-11-02 20:00 472

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio * I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myelom...

2023-11-02 20:00 951

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...

2023-11-02 15:58 1138

Precision, Effectiveness, and Intelligence: Explore the Latest Trend of Healthcare and Medical Equipment Industry at 134th Canton Fair

GUANGZHOU, China, Nov. 1, 2023 /PRNewswire/ -- As the public is paying increasing attention to health management, the 5-day onsite exhibition of Phase 3 of the 134th Canton Fair held from October 31st to November 4th will present nearly 600 quality exhibitors in medical and healthcare industries ...

2023-11-02 08:00 1595

Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. ("Heartseed"), a Tokyo-based bio...

2023-11-02 00:00 1494

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

* Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therap...

2023-11-01 21:08 1565

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

~ First Phase: Joint Development of Chronic Pain VR with U.S. Chronic Pain Experts TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North Ame...

2023-11-01 21:00 1755

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunother...

2023-11-01 20:00 1271

Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T

* Anbal-cel targeting DLBCL completes phase 2 trial * Anticipation growing over Korea's first CAR-T therapy ahead of regulatory review * Commercial manufacturing scheduled in 2025 at Korea's only CAR-T GMP facility DAEJEON, South Korea, Nov. 1, 2023 /PRNewswire/ -- Curocell, South Korea ...

2023-11-01 16:23 1347

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

WASHINGTON, Oct. 31, 2023 /PRNewswire/ -- Complete Genomics, a pioneering genomic sequencing company, announced today at the American Society of Human Genetics (ASHG) Annual Meeting,Nov. 1-5, in Washington details on the commercial and technical momentum it has demonstrated in the last 10 months ...

2023-10-31 21:44 1440

Lunit Joins as an Associate Partner with the World Economic Forum

- Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and collaboration in the realm of AI-driven cancer care SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and th...

2023-10-31 21:00 1434
1 ... 38394041424344 ... 260